propafenone has been researched along with Wolff-Parkinson-White Syndrome in 42 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 9.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 9.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 9.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 9.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 9.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels." | 7.74 | Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome. ( Fragakis, N; Iliadis, I; Katsaris, G; Lambrou, A; Papanastasiou, S, 2007) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 7.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 7.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| " The remaining side effects, if present, were tolerated, and dosage dependent." | 5.27 | Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Borggrefe, M; Breithardt, G; Seipel, L; Wiebringhaus, E, 1984) |
| "To evaluate the electrophysiological effects of intravenous propafenone in the anterograde and retrograde effective refractory period of the accessory pathways (AP), in patients with Wolff-Parkinson-White syndrome." | 5.07 | [Acute effects of propafenone in patients with ventricular pre-excitation]. ( Cruz Filho, F; Fagundes, ML; Lorga, AM; Loyola, LH; Maia, IG; Pimenta, J, 1993) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 5.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 5.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 5.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 5.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 5.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels." | 3.74 | Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome. ( Fragakis, N; Iliadis, I; Katsaris, G; Lambrou, A; Papanastasiou, S, 2007) |
| " After 24-hour Holter ECG monitoring had revealed Wolff-Parkinson-White syndrome as cause of the PSVT, propafenone was administered (15 mg/kg daily) and has prevented further recurrence of the tachycardia." | 3.69 | [Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants]. ( Gessler, P; Haas, NA; König, SA; Pufahl, C; Teufel, M, 1994) |
| "We describe a case of dangerous acceleration of conduction through an accessory pathway produced by the Class IC agent propafenone during routine electrophysiological study of a patient with Wolff-Parkinson-White syndrome." | 3.68 | Acceleration of conduction within an accessory pathway with propafenone. ( Holt, P; Sowton, GE; Sulke, AN, 1990) |
| "A 46 year-old woman with Wolff-Parkinson-White syndrome (postero-septal accessory pathway), symptomatic for recurrent episodes of nonsustained paroxismal supraventricular tachycardia (PSVT), was empirically treated with propafenone (600 mg/day)." | 3.68 | Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia. ( Calvi, V; di Bona, G; Manzoli, U; Montenero, AS; Natale, A; Santarelli, P, 1990) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 3.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "Noninvasive stress and pharmacologic tests with procainamide and propafenone were studied as methods to identify patients with Wolff-Parkinson-White syndrome (WPW) who would otherwise be judged at risk of sudden death on the basis of electrophysiologic criteria: the shortest RR interval during induced atrial fibrillation less than or equal to 250 ms or accessory pathway anterograde effective refractory period less than or equal to 250 ms." | 3.67 | Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. ( Brusca, A; Gaita, F; Giustetto, C; Mangiardi, L; Riccardi, R, 1989) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 3.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| ") and oral propafenone were evaluated in 14 patients with Wolff-Parkinson-White syndrome and in 10 patients with atrioventricular (AV) nodal reentrant tachycardia." | 3.67 | Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. ( Lüderitz, B; Manz, M; Steinbeck, G, 1985) |
| " Little justification for the use of agents or dosing in children is available." | 2.40 | Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. ( Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997) |
| "Among them 29 cases with SVT (including WPW syndrome in 11, paroxysmal AF or Af in 3) and the other two cases were studied for other reasons." | 1.28 | [Electrophysiologic effects of intravenous propafenone]. ( Song, YC; Sun, RL; Zhang, S, 1989) |
| "Thus propafenone can produce rate-dependent failure of ventricular capture which is associated with marked prolongation of refractoriness and QRS duration suggesting a marked use-dependent drug effect in selected patients." | 1.28 | Rate-dependent failure of ventricular capture in patients treated with oral propafenone. ( Almendral, J; Arenal, A; Delcan, JL; Josephson, ME; San Román, D; Soriano, J, 1992) |
| " The remaining side effects, if present, were tolerated, and dosage dependent." | 1.27 | Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Borggrefe, M; Breithardt, G; Seipel, L; Wiebringhaus, E, 1984) |
| " The same holds true for general tolerance: in 2 cases drug administration is discontinued and 11 patients present neurologic and digestive troubles improving after lowering the dosage or increasing the fractionation." | 1.27 | [Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation]. ( Cosnay, P; Fauchier, JP; Kapusta, P; Moquet, B; Rouesnel, P; Vrancea, F, 1986) |
| "Propafenone was administered during electrophysiologic testing to determine its efficacy and safety for terminating and preventing reinduction of paroxysmal supraventricular reentrant tachycardia." | 1.27 | Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. ( Gersh, BJ; Hammill, SC; Holmes, DR; McLaran, CJ; Osborn, MJ; Wood, DL, 1987) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (42.86) | 18.7374 |
| 1990's | 20 (47.62) | 18.2507 |
| 2000's | 2 (4.76) | 29.6817 |
| 2010's | 2 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Rosa, F | 1 |
| Mancuso, P | 1 |
| Chiatto, M | 1 |
| Calvelli, A | 1 |
| De Donato, V | 1 |
| Mazza, S | 1 |
| Spadafora, G | 1 |
| Paech, C | 1 |
| Flosdorff, P | 1 |
| Gebauer, RA | 1 |
| Koshumbaeva, KM | 1 |
| Belokopit, IN | 1 |
| Makhanov, DI | 1 |
| Nugmanova, MN | 1 |
| Fragakis, N | 1 |
| Iliadis, I | 1 |
| Papanastasiou, S | 1 |
| Lambrou, A | 1 |
| Katsaris, G | 1 |
| Coumel, P | 1 |
| Leclercq, JF | 1 |
| Assayag, P | 1 |
| Furlanello, F | 2 |
| Vergara, G | 2 |
| Dal Forno, P | 2 |
| Disertori, M | 2 |
| Inama, G | 2 |
| Breithardt, G | 2 |
| Borggrefe, M | 2 |
| Wiebringhaus, E | 1 |
| Seipel, L | 1 |
| Neumann, G | 1 |
| Grube, E | 1 |
| Funke, H | 1 |
| Bettini, R | 1 |
| Stefenelli, C | 1 |
| Zuechi, S | 1 |
| Bösche, J | 1 |
| Mattern, R | 1 |
| Chen, X | 1 |
| Martinez-Rubio, A | 1 |
| Hief, C | 1 |
| Haverkamp, W | 1 |
| Hindricks, G | 1 |
| Marafioti, V | 1 |
| Carbonieri, E | 1 |
| Zardini, P | 1 |
| Haas, NA | 1 |
| Pufahl, C | 1 |
| König, SA | 1 |
| Gessler, P | 1 |
| Teufel, M | 1 |
| Auricchio, A | 2 |
| Auricchio, U | 1 |
| Chiariello, L | 1 |
| Maia, IG | 1 |
| Cruz Filho, F | 1 |
| Fagundes, ML | 1 |
| Loyola, LH | 1 |
| Pimenta, J | 1 |
| Lorga, AM | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Luedtke, SA | 1 |
| Kuhn, RJ | 1 |
| McCaffrey, FM | 1 |
| Gómez-Barrado, JJ | 1 |
| García-Rubira, JC | 1 |
| Turégano Albarrán, S | 1 |
| Pavón García, M | 1 |
| Hidalgo Urbano, R | 1 |
| Montes Ramírez, JM | 1 |
| Cruz Fernández, JM | 1 |
| Manolis, AS | 1 |
| Katsaros, C | 1 |
| Cokkinos, DV | 1 |
| Camm, AJ | 2 |
| Katritsis, D | 1 |
| Nunain, SO | 1 |
| Soriano, J | 1 |
| Almendral, J | 1 |
| Arenal, A | 1 |
| San Román, D | 1 |
| Delcan, JL | 1 |
| Josephson, ME | 1 |
| O'Nunain, S | 1 |
| Garratt, CJ | 1 |
| Linker, NJ | 1 |
| Gill, J | 1 |
| Ward, DE | 1 |
| Goy, JJ | 1 |
| Fromer, M | 1 |
| Schlaepfer, J | 1 |
| Kappenberger, L | 1 |
| Santinelli, V | 2 |
| Turco, P | 2 |
| De Paola, M | 2 |
| Smimmo, D | 2 |
| Giasi, M | 1 |
| Santinelli, C | 1 |
| Chiariello, M | 2 |
| Condorelli, M | 2 |
| Wu, Z | 1 |
| Montenero, AS | 1 |
| Natale, A | 1 |
| di Bona, G | 1 |
| Calvi, V | 1 |
| Santarelli, P | 1 |
| Manzoli, U | 1 |
| Boahene, KA | 1 |
| Klein, GJ | 1 |
| Yee, R | 1 |
| Sharma, AD | 1 |
| Fujimura, O | 1 |
| Vassiliadis, I | 1 |
| Papoutsakis, P | 1 |
| Kallikazaros, I | 1 |
| Stefanadis, C | 1 |
| Sulke, AN | 1 |
| Holt, P | 1 |
| Sowton, GE | 1 |
| Kunze, KP | 1 |
| Schlüter, M | 1 |
| Geiger, M | 1 |
| Kuck, KH | 1 |
| Zhang, S | 1 |
| Sun, RL | 1 |
| Song, YC | 1 |
| Dubuc, M | 1 |
| Kus, T | 1 |
| Campa, MA | 1 |
| Lambert, C | 1 |
| Rosengarten, M | 1 |
| Shenasa, M | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Riccardi, R | 1 |
| Mangiardi, L | 1 |
| Brusca, A | 1 |
| Lacroix, H | 1 |
| Frank, R | 1 |
| Tonet, JL | 1 |
| Fontaine, G | 1 |
| Wajman, A | 1 |
| Squeir, S | 1 |
| Grosgogeat, Y | 1 |
| Barbieri, O | 1 |
| Cammalleri, G | 1 |
| Gruttadauria, G | 1 |
| Rugiano, A | 1 |
| Vancheri, F | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Moquet, B | 1 |
| Rouesnel, P | 1 |
| Kapusta, P | 1 |
| Vrancea, F | 1 |
| Ludmer, PL | 1 |
| McGowan, NE | 1 |
| Antman, EM | 1 |
| Friedman, PL | 1 |
| Hammill, SC | 1 |
| McLaran, CJ | 1 |
| Wood, DL | 1 |
| Osborn, MJ | 1 |
| Gersh, BJ | 1 |
| Holmes, DR | 1 |
| Manz, M | 2 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Lüderitz, B | 2 |
| Steinbeck, G | 1 |
3 reviews available for propafenone and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
[Ventricular preexcitation: is risk stratification feasible?].
Topics: Adolescent; Adult; Age Distribution; Ajmaline; Atrioventricular Node; Catheter Ablation; Child; Chil | 2010 |
[Progress in arrhythmology].
Topics: Adolescent; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Cardiac P | 1981 |
Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Ch | 1997 |
10 trials available for propafenone and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Efficacy of ajmaline and propafenone in patients with accessory pathways: a prospective randomized study.
Topics: Accessory Nerve; Adolescent; Adult; Aged; Ajmaline; Atrial Fibrillation; Electrophysiology; Female; | 1994 |
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Exercise Test; Female; Flecainide; Humans; Male; | 1994 |
[Acute effects of propafenone in patients with ventricular pre-excitation].
Topics: Adolescent; Adult; Atrioventricular Node; Electrocardiography; Female; Heart Block; Humans; Male; Mi | 1993 |
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Atrial Function; Cardiac Catheterization; Cardiac Pacing, Artificial; Flecainid | 1992 |
Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Exercise; Exercise Te | 1992 |
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Propafenon | 1991 |
Propafenone in Wolff-Parkinson-White syndrome at risk.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Fema | 1990 |
Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Echocardiography; Female; Humans; Male; Middle Aged; P | 1990 |
Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome.
Topics: Adult; Cardiac Pacing, Artificial; Clinical Trials as Topic; Double-Blind Method; Electrophysiology; | 1989 |
Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Topics: Adolescent; Adult; Atrial Fibrillation; Clinical Trials as Topic; Electrophysiology; Female; Follow- | 1987 |
29 other studies available for propafenone and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Pharmacologic cardiac resynchronization of a 1-year-old boy with severe left ventricular dysfunction.
Topics: Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy; Echocardiography; Electrocardiography; Hu | 2012 |
[Preventive efficacy of propafenone, its effect on functional state of the heart during long-term treatment of patients with paroxysmal atrioventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Hea | 2006 |
Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.
Topics: Brugada Syndrome; Electrocardiography; Female; Humans; Lithium Compounds; Middle Aged; Propafenone; | 2007 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
[Clinical experience with propafenone in paroxysmal supraventricular reciprocating tachycardias].
Topics: Anti-Arrhythmia Agents; Drug Evaluation; Female; Heart Rate; Humans; Male; Propafenone; Propiophenon | 1984 |
Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Fe | 1984 |
[The value of antitachycardia pacemaker therapy in patients with Wolff-Parkinson-White syndrome].
Topics: Anti-Arrhythmia Agents; Bundle of His; Digitalis Glycosides; Disopyramide; Electrocardiography; Huma | 1983 |
[Fatal poisoning with the antiarrhythmic agent propafenon].
Topics: Adult; Anti-Arrhythmia Agents; Chromatography, Gas; Forensic Medicine; Humans; Male; Propafenone; Pr | 1980 |
Cases in electrocardiography.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Propafenone; Tachycardia, Par | 1995 |
[Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants].
Topics: Adenosine Triphosphate; Digoxin; Drug Therapy, Combination; Echocardiography; Electrocardiography; E | 1994 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
[Circulatory arrest after combined intravenous drugs for the treatment of orthodromic circular tachycardia of Wolff-Parkinson-White syndrome].
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Female; Heart Arrest; Humans; Middle | 1997 |
Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing.
Topics: Adrenergic beta-Antagonists; Adult; Cardiac Pacing, Artificial; Drug Therapy, Combination; Female; F | 1992 |
Rate-dependent failure of ventricular capture in patients treated with oral propafenone.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Electrocardiography; Heart Rate; Heart Ventr | 1992 |
Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrioventricular Node; Cardiac Catheterization; Electrocardiography; Electrophysi | 1991 |
[Clinical electrophysiologic study in paroxysmal reentry tachycardia treated by rhythnorma].
Topics: Electrophysiology; Female; Heart; Humans; Male; Propafenone; Tachycardia, Atrioventricular Nodal Ree | 1990 |
Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia.
Topics: Administration, Oral; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecainide; Follow-Up | 1990 |
Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Drug Administration Schedule; Echocardiography; Electrocardiography; Ele | 1990 |
Acceleration of conduction within an accessory pathway with propafenone.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1990 |
Diprafenone for treatment of Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Electric Stimulati | 1989 |
[Electrophysiologic effects of intravenous propafenone].
Topics: Adolescent; Adult; Electrocardiography; Electrophysiology; Female; Humans; Injections, Intravenous; | 1989 |
Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death.
Topics: Adolescent; Adult; Child; Death, Sudden; Exercise Test; Female; Humans; Male; Middle Aged; Procainam | 1989 |
[Effect of oral propafenon on accessory pathways of atrioventricular conduction].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Electrocardiography; Female; Heart C | 1985 |
[I.v. propafenone in supraventricular paroxysmal tachyarrhythmias in patients with Wolff-Parkinson-White syndrome. 2 clinical cases].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Infusions, Intravenous; Propafenone | 1988 |
[Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Humans; Injections, Intravenous; Mal | 1986 |
Wolff-Parkinson-White at risk and propafenone.
Topics: Administration, Oral; Adult; Female; Humans; Pregnancy; Propafenone; Wolff-Parkinson-White Syndrome | 1988 |
Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
Topics: Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Conduction System; Hemodynamics; | 1987 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |
Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Child; | 1985 |